Biotech

Article Index

This Biotech ETF Will Rise from the Ashes on Feb. 3

By , America's No. 1 Pattern Trader, Money Morning • @powerproftrades -

2019 was just coming to an end in central China when people began suffering from runny noses, sore throats, and pesky coughs...

But it was the start of winter - flu-season, the peak time for the common cold.

The symptoms were anything but out of the ordinary.

Now, less than a month later, at least 170 people have died as I'm writing, and the number of people infected has skyrocketed to 7,700 - that's nearly twice as many new infections in just one day.

The pneumonia-like virus has spread from mainland China across the world, with cases confirmed in more than a dozen countries - five already in the U.S.

Needless to say, the word coronavirus is now plastered across every news network.

But the widespread fear isn't discriminatory.

It's punishing stocks with no relation to the virus' impacts as well.

Without any business in China, these companies will be the first to recover once the fear subsides. And if you get in now, you'll be seeing profits the moment recovery begins.

In fact, this stock is about to rise like a phoenix from the ashes...

The 3 Biotech Stocks You Need in Your Portfolio

By , Associate Editor, Money Morning -

The numbers are staggering. Over the next six years, the biotech market is expected to add an additional $593 billion in value - a 419% increase over the size of today's biotech market.

Growth like this is why Wall Street is rushing hand over foot to buy the most lucrative biotech stocks available. With thousands of biotech stocks on the market, identifying the best biotech stocks to buy is incredibly difficult.

However, using the Money Morning Stock VQScore™ system, we've identified 3 biotech stocks that are on track to deliver triple-digit returns.

The One Thing You Must Know to Hit It Big in Biotech

By , Biotech Investing Specialist, Money Morning -

When you're evaluating a biotech, or even a full-fledged pharmaceutical company, you'll want to look at its product pipeline, upcoming catalysts, and financial indicators.

But the most important asset it possesses, the heartbeat that drives everything else, is its intellectual property (patent) portfolio...

That's what will make it attractive for acquisition, merger, or licensing deals.

And that's what protects its products from marauding generic drug manufacturers, who will produce copycat therapies and sell them at cutthroat prices.

For a drug development company, that spells disaster.

When a drug goes generic, it's not unusual for the original brand manufacturer's market share to drop more than 40%...

How to Spot Biotech Shares with "Blockbuster" Potential

By , Biotech Investing Specialist, Money Morning -

biotech shares

The FDA's Expedited Programs help promising new therapies for seriously ill patients move through the approval process as quickly as possible.

That's great for patients, but there's a "side effect," one that offers a huge advantage to investors.

You see, these programs can serve to spotlight some of the biggest potential moneymaking drugs in biotech.

And here's exactly how you find them...

Biotech Stocks 2017: The Best Way to Beat the Market This Year

By , Money Morning -

biotech stocks 2017

Biotech stocks in 2017 are beating the markets with nearly double the gains of the Dow. And the biotech sector is expected to continue beating the markets this year.

But not all biotech stocks are worth the investment. Picking the right stocks is crucial in beating the markets this year.

And our expert has a stock pick that could nearly double your money in the next 12 months...

You Already Own the Cannabis Biotech That Could End the U.S. Opioid Crisis

By , Defense + Tech Specialist, Money Morning • @Robinson_STI -

cannabis biotech

You don't need me to tell you that we're in the middle of a huge and growing opioid crisis.

I'm almost certain you've seen the statistics - and you've likely seen the evidence yourself.

Perhaps you live in a region that's been devastated by heroin and prescription opioids.

Or maybe you've seen an addict collapse in public.

Odds suggest many of you have friends and loved ones who have seen their lives destroyed by this epidemic.

But if you haven't seen the numbers - or if you're lucky enough to live in one of the few places that this crisis hasn't touched - let me show a few to you...

How to Protect Your Biotech Profits from This Legal Limbo

By , Biotech Investing Specialist, Money Morning -

biotech profits

Gilead Sciences Inc.'s Sovaldi was a real breakthrough in the fight against the chronic liver disease hepatitis C (HCV). The condition may show no symptoms for years after initial infection but can slowly become debilitating.

Hepatitis C affects as many as 200 million people worldwide, and before Sovaldi, the approved drug regimen could treat only about 50% of cases and could cause serious side effects. Treatment was generally long - 24 to 48 weeks - and arduous.

Sovaldi, on the other hand, could cure more than 90% of cases in a matter of weeks at a cost, in the United States, of around $94,000. The pricing caused controversy, but the drug proved transformative for HCV patients, their families, and doctors.

Sovaldi also proved a huge windfall for investors when it received FDA approval in 2013 and entered the pharmaceutical marketplace the following year.

So far, Gilead shareholders have seen a 2:1 split, several dividend payouts, and gains of more than 155% since 2013. Sales of Sovaldi and Gilead's other HCV drug, Harvoni, topped $12.5 billion in 2015 alone.

There's just one big, expensive problem...